Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Recruiting N/A Interventional Study
Lymphoma Myeloma Cytokine Release Syndrome Immune Effector Cell Associated Neurotoxicity Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 and older
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
40 (estimated)
Sponsor
University of Utah · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and i…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * age \>21 * confirmed diagnosis of lymphoma or myeloma * commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Access to a working telephone line in their home or a cell phone. Exc…
Contacts

Aileen Gabriel

801-585-3229

aileen.gabriel@utah.edu

CONTACT